By Connor Hart
AngioDynamics raised its full-year sales outlook after logging a higher top line in its fiscal second quarter, as the company scooped up market share from competitors.
The medical-technology company on Tuesday said it now expects sales of $312 million to $314 million for the year, up from a prior outlook of $308 million to $313 million. It backed its outlook for an adjusted loss of 33 cents to 23 cents a share.
The company noted that its forecast includes an up-to-$6 million impact from tariffs. Analysts polled by FactSet are looking for an adjusted loss of 33 cents a share on sales of $310.3 million.
The new sales outlook came as AngioDynamics narrowed its loss to $6.35 million, or 15 cents a share, for its quarter ended Nov. 30, from a loss of $10.7 million, or 26 cents a share, a year earlier.
On an adjusted per-share basis, AngioDynamics broke even. Analysts had expected an adjusted loss of 10 cents a share.
Quarterly sales gained 8.8% to $79.4 million, topping Wall Street models for $76.4 million.
Sales of medical devices rose 5.6% to $43.8 million, while sales of medical technologies climbed 13% to $35.7 million..
Chief Executive Jim Clemmer said the company's strategic transformation is bearing fruit, as its medical technologies continue to gain share. He added the company will capitalize on momentum by continuing to invest across its medical technology portfolio.
Clemmer also said he intends to retire next year, prompting AngioDynamics' board to establish a new committee to conduct a search for the company's next CEO.
Shares rose 8.7%, to $14.38, in premarket trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
January 06, 2026 06:27 ET (11:27 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Comments